The products I work on are mostly monoclonal antibodies (and the occasional gene therapy product mixed in). So, the types of diseases they are used to treat vary. To be honest, I work on the process/formulation side of the development pipleline and the actual clinical treatment part is pretty much inconsequential to what I do. Some of the past programs I have worked on include treatments for asthma, eczema, multiple myeloma, breast cancer, MS, hemophilia, and tons of others that I don’t remember. Often, when dealing with antibodies, the same medicine can be effective for multiple indications.
The finished vials, post-lyophilization, sealing, labeling, and packaging, are sent to infusion clinics. There, clinicians will add water to the vials to reconstitute the drugs and then administer them to patients via IV (usually).
The products I work on are mostly monoclonal antibodies (and the occasional gene therapy product mixed in). So, the types of diseases they are used to treat vary. To be honest, I work on the process/formulation side of the development pipleline and the actual clinical treatment part is pretty much inconsequential to what I do. Some of the past programs I have worked on include treatments for asthma, eczema, multiple myeloma, breast cancer, MS, hemophilia, and tons of others that I don’t remember. Often, when dealing with antibodies, the same medicine can be effective for multiple indications.
The finished vials, post-lyophilization, sealing, labeling, and packaging, are sent to infusion clinics. There, clinicians will add water to the vials to reconstitute the drugs and then administer them to patients via IV (usually).